Effects of Intraduodenal Glutamine on Incretin Hormone and Insulin Release, the Glycemic Response to an Intraduodenal Glucose Infusion, and Antropyloroduodenal Motility in Health and Type 2 Diabetes

Jessica Chang, MBBS, MPhil1,2
Tongzhi Wu, MBBS1,2
Jerry R. Greenfield, MBBS1,2

Objective—Glutamine reduces postprandial glycemia when given before oral glucose. We evaluated whether this is mediated by stimulation of insulin and/or slowing of gastric emptying.

Research Design and Methods—Ten healthy subjects were studied during intraduodenal (ID) infusion of glutamine (7.5 or 15 g) or saline over 30 min, followed by glucose (75 g over 100 min), while recording antropyloroduodenal pressures. Ten patients with type 2 diabetes mellitus (T2DM) were also studied with 15 g glutamine or saline.

Results—ID glutamine stimulated glucagon-like peptide 1 (GLP-1; healthy: P < 0.05; T2DM: P < 0.05), glucose-dependent insulinotropic polypeptide (GIP; P = 0.098; P < 0.05), glucagon (P < 0.01; P < 0.001), insulin (P = 0.05; P < 0.01), and phasic pyloric pressures (P < 0.05; P < 0.05), but did not lower blood glucose (P = 0.077; P = 0.5).

Conclusions—Glutamine does not lower glycemia after ID glucose, despite stimulating GLP-1, GIP, and insulin, probably due to increased glucagon. Its capacity for pyloric stimulation suggests that delayed gastric emptying is a major mechanism for lowering glycemia when glutamine is given before oral glucose.

Diabetes Care 36:2262–2265, 2013

From the 1Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia, Australia; the 2Centre of Clinical Research Excellence in Nutritional Physiology, Interventions, and Outcomes, Adelaide, South Australia, Australia; the 3Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Sydney, Faculty of Medicine, University of New South Wales, New South Wales, Australia; and the 4Department of Endocrinology, St. Vincent’s Hospital, Darlinghurst, New South Wales, Australia.

Corresponding author: Christopher K. Rayner, chris.rayner@adelaide.edu.au.

Received 17 August 2012 and accepted 1 February 2013.

DOI: 10.2337/dc12-1663

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Figure 1—Effects of ID saline (control) and 7.5 or 15 g glutamine infusions on blood glucose (A and B), plasma GLP-1 (C and D), plasma GIP (E and F), serum insulin (G and H), and plasma glucagon (I and J) concentrations in 10 healthy subjects and 9 patients with T2DM, before (t = 0–30 min) and during (t = 30–130 min) ID glucose infusion. *P = 0.05 for greater iAUC for 15 vs. 7.5 g glutamine or saline (127.1 ± 33.1 vs. 45.1 ± 12.7 vs. 51.4 ± 23.1 pmol/L/min), **P < 0.05 for greater iAUC for 15 vs. 7.5 g glutamine (1,715 ± 440 vs. 1,099 ± 354 pmol/L/min), αP < 0.05 for greater iAUC for 15 g glutamine vs. saline (84.6 ± 19.3 vs. 37.0 ± 27.1 pmol/L/min), βP < 0.05 for greater iAUC for 15 g glutamine vs. saline (110.3 ± 36.6 vs. 10.8 ± 7.0 pmol/L/min), c P = 0.05 for greater iAUC for 15 vs. 7.5 g glutamine or saline (32.3 ± 9.4 vs. 20.1 ± 8.4 vs. 8.3 ± 3.9 mU/L/min), δP < 0.01 for greater iAUC for 15 g glutamine vs. saline (62.8 ± 19.9 vs. 5.7 ± 3.4 mU/L/min), δδP < 0.05 for greater iAUC for 15 g
were compared using one-factor ANOVA for healthy subjects and paired t tests for patients with T2DM. Post hoc comparisons, adjusted for multiple comparisons by Bonferroni’s correction, were performed if ANOVAs revealed significant effects. Calculations were done with SPSS 19 software (IBM Corporation, Armonk, NY). Data are means ± SE. Statistical significance was accepted at P < 0.05.

RESULTS—The study was well tolerated; one patient with T2DM was excluded due to marked nausea with glutamine.

Blood glucose was unchanged during ID glutamine/saline infusion. The increase in blood glucose during ID glucose infusion did not differ between treatments in health or T2DM (Fig. 1A and B).

Plasma GLP-1 increased during ID glutamine infusion in health (P = 0.05) and T2DM (P < 0.05). During ID glucose infusion, GLP-1 concentrations in health increased more after 15 g glutamine than 7.5 g glutamine or saline (P < 0.05), whereas in T2DM, the increment was nonsignificantly greater after 15 g glutamine (P = 0.056; Fig. 1C and D).

Plasma GIP increased during ID glutamine infusion in T2DM (P < 0.05), but not significantly in health (P = 0.098). During ID glucose infusion, GIP concentrations increased similarly with all treatments in both groups (Fig. 1E and F).

Serum insulin increased slightly during ID glutamine infusion in health (P = 0.05) and T2DM (P < 0.01). During ID glucose infusion, insulin concentrations increased without any difference between treatments in health, whereas in T2DM, the increment in insulin was greater after glutamine than after saline (P < 0.05; Fig. 1G and H).

Plasma glucagon increased during ID glutamine infusion in health, with a greater increment for 15 g than for 7.5 g glutamine (P < 0.005), and also increased in T2DM (P < 0.005). During ID glucose infusion, glucagon concentrations in health were greater after 15 and 7.5 g glutamine than after saline (P < 0.01) and were greater after glutamine in T2DM (P < 0.001; Fig. 1I and J).

Antropyloroduodenal pressures
There were more IPPWs during 15 g glutamine infusion than 7.5 g glutamine or saline in health (19.5 ± 6.7 vs. 7.9 ± 3.6 vs. 3.6 ± 1.6, P < 0.05), and more IPPWs during glutamine than saline in T2DM (16.1 ± 5.1 vs. 5.5 ± 1.8, P < 0.05). During ID glucose infusion, the number of IPPWs did not differ between treatments in either group (healthy: 28.4 ± 8.7 vs. 24.5 ± 8.7 vs. 24.5 ± 8.2, T2DM: 57.9 ± 9.4 vs. 60.5 ± 14.7).

The number of antral waves did not differ between treatments during ID glutamine/saline infusion in health (26.5 ± 10.7 vs. 30.5 ± 7.7 vs. 44.3 ± 15.1), but antral waves were fewer in T2DM after glutamine compared with saline (10.6 ± 5.6 vs. 32.9 ± 10.3, P < 0.05). During ID glucose infusion, the number of antral waves did not differ between treatments in either group (healthy: 18.9 ± 15.2 vs. 20.2 ± 12.9 vs. 22.9 ± 8.7, T2DM: 10.5 ± 2.3 vs. 14.3 ± 9.2).

The number of duodenal waves did not differ between treatments during ID glutamine/saline infusion in health (289.7 ± 50.4 vs. 376.6 ± 43.8 vs. 295.4 ± 62.0; T2DM: 215.3 ± 63.2 vs. 213.9 ± 39.6) or ID glucose infusion (healthy: 160.5 ± 72.6 vs. 156.4 ± 64.1 vs. 128.3 ± 33.8; T2DM: 75.1 ± 24.7 vs. 84.9 ± 32.9) in either group.

CONCLUSIONS—We demonstrated that 15 g ID glutamine stimulated GLP-1 secretion in health and T2DM, associated with modest insulin stimulation. However, the glycemic response to a subsequent ID glucose load was not diminished, probably because of increased glucagon. Glutamine stimulated pyloric motility, which would delay gastric emptying. The effects of glutamine on hormone secretion and motility appeared to be dose-dependent, because the effects of 7.5 g glutamine were no different from saline.

We infused glutamine over 30 min based on the timing of the maximal GLP-1 response to oral glutamine (6). A higher dose might have had greater effects, but in pilot studies, 30 g infused over 30 min tended to induce nausea. Despite relatively few subjects, the effects were consistent, and it is unlikely that studying more subjects would alter the outcomes substantially. An additional day giving glucose orally would be of interest, as would an evaluation of other amino acids and inclusion of patients with less well controlled diabetes. Nevertheless, slowing of gastric emptying appears the predominant mechanism by which glutamine can lower glycemia.

Acknowledgments—This work was funded by a grant awarded by the National Health and Medical Research Council of Australia (Grant No. 627139).

No potential conflicts of interest relevant to this article were reported.

J.C. contributed to study design, subject recruitment, data collection and analyses, and drafting of the manuscript. T.W. contributed to data collection, statistical analysis, and preparation of the figures. J.R.G. and M.H. contributed to study conceptualization and design, data interpretation, and critical review of the manuscript. D.S.-B. contributed to data interpretation and critical review of the manuscript. C.K.R. contributed to study design and data interpretation and was responsible for overall supervision and the final content of the manuscript. C.K.R is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Judith Wishart and Scott Standfield, of the Discipline of Medicine, University of Adelaide, who performed the hormone assays, and Kylie Lange, also of the Discipline of Medicine, University of Adelaide, who provided expert statistical advice.

References
1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881–885
2. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24:371–381
3. Horowitz M, Dent J, Fraser R, Sun W, Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994;39(Suppl.):75–135
4. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in glutamine vs. saline (5,994 ± 1,783 vs. 4,689 ± 1,553 mU/L/min), #P < 0.005 for greater iAUC for 15 vs. 7.5 g glutamine (289.7 ± 77.9 vs. 183.9 ± 41.1 pg/mL/min), ##P < 0.01 for greater iAUC for 15 and 7.5 g glutamine vs. saline (529.5 ± 100.8 and 363.5 ± 53.4 vs. 132.0 ± 65.3 pg/mL/min), ¥P < 0.005 for greater iAUC for 15 g glutamine vs. saline (362.1 ± 77.1 vs. 16.6 ± 11.1 pg/mL/min), and ¥¥P < 0.001 for greater iAUC for 15 g glutamine vs. saline (2,131.8 ± 280.1 vs. 263.2 ± 117.2 pg/mL/min).
early noninsulin-dependent diabetes mellitus. J Nucl Med 1996;37:1643–1648
5. Samocha-Bonet D, Wong O, Synnott EL, et al. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr 2011;141:1233–1238
6. Greenfield JR, Farooqi IS, Keogh JM, et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 2009;89:106–113
7. Lobo DN, Hendry PO, Rodrigues G, et al. Gastric emptying of three liquid oral preoperative metabolic preconditioning regimens measured by magnetic resonance imaging in healthy adult volunteers: a randomised double-blind, crossover study. Clin Nutr 2009;28:636–641
8. Ma J, Stevens JE, Cukier K, et al. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 2009;32:1600–1602
9. Samsom M, Smout AJ, Hebbard G, et al. A novel portable perfused manometric system for recording of small intestinal motility. Neurogastroenterol Motil 1998;10:139–148